A new variation of the CRISPR-Cas9 gene editing system makes it easier to re-engineer massive quantities of cells for therapeutic applications. The approach, developed at Gladstone Institutes and UC San Francisco (UCSF), lets scientists introduce especially long DNA sequences to precise locations in
T cells used in immunotherapy treatments can get exhausted by the task of fighting cancer cells or get shutdown as they enter tumors. Using a CRISPR-based edit on these cells’ genomes, researchers at UC San Francisco and Gladstone Institutes have rendered the therapeutic cells more resilient. The
A new UC San Francisco study sheds light on the diversity within the most common type of pediatric liver tumor and suggests a way forward for more precise chemotherapy treatment. The study, publishing in Nature Communications on August 25, used single-cell transcriptomic techniques to analyze
Watch the video below from ABC7 News.
Eleven investigators and teams were awarded grants in support of cancer research projects in the spring 2022 cycle of the UCSF Resource Allocation Program (RAP). Funded by various agencies across UCSF, the awards span a range of topics from cancer screening to image-guided drug delivery to